Adamas Pharmaceuticals

Adamas is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system (CNS). We achieve this by enhancing the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products.
Company Growth (employees)
Type
Public
HQ
Emeryville, US
Founded
2002
Size (employees)
69 (est)+12%
Adamas Pharmaceuticals was founded in 2002 and is headquartered in Emeryville, US

Key People at Adamas Pharmaceuticals

William Dawson

William Dawson

CFO
David Chernoff

David Chernoff

Chief Medical Officer
David Mahoney

David Mahoney

Director
Mary Jean Stempien

Mary Jean Stempien

VP, Clinical Research

Adamas Pharmaceuticals Office Locations

Adamas Pharmaceuticals has an office in Emeryville
Emeryville, US (HQ)
750 1900 Powell St

Adamas Pharmaceuticals Data and Metrics

Adamas Pharmaceuticals Financial Metrics

Adamas Pharmaceuticals's revenue was reported to be $572 k in FY, 2016 which is a 70% decrease from the previous period.
USD

Revenue (FY, 2016)

572 k

Revenue growth (FY, 2015 - FY, 2016), %

(70%)

Net income (FY, 2016)

(60.1 m)

EBIT (FY, 2016)

(61 m)

Market capitalization (27-Jun-2017)

377.4 m

Closing share price (27-Jun-2017)

17.4

Cash (31-Dec-2016)

23.7 m
Adamas Pharmaceuticals's current market capitalization is $377.4 m.
USDFY, 2014FY, 2015FY, 2016

Revenue

55.8 m1.9 m572 k

Revenue growth, %

(97%)(70%)

R&D expense

21.9 m35.9 m31.2 m

General and administrative expense

15.5 m23.5 m

Operating expense total

37.3 m59.4 m61.6 m

EBIT

18.5 m(57.4 m)(61 m)

EBIT margin, %

33%(2998%)(10662%)

Interest income

(917 k)363 k811 k

Pre tax profit

17.6 m(57.1 m)(60.2 m)

Income tax expense

(7.4 m)(5.3 m)(115 k)

Net Income

10.2 m(51.8 m)(60.1 m)
USDFY, 2014FY, 2015FY, 2016

Cash

61.4 m33.1 m23.7 m

Accounts Receivable

524 k1.3 m794 k

Inventories

645 k5.1 m2.5 m

Current Assets

123.5 m113.2 m117 m

PP&E

1.2 m2.4 m3.2 m

Total Assets

161.2 m128.7 m142.5 m

Accounts Payable

3.7 m3.1 m3.6 m

Current Liabilities

12.5 m11.8 m9.7 m

Non-Current Liabilities

749 k547 k

Total Liabilities

12.6 m10.3 m

Additional Paid-in Capital

157.6 m178.5 m254.6 m

Retained Earnings

(10.3 m)(62.2 m)(122.2 m)

Total Equity

147.1 m116.2 m132.2 m

Financial Leverage

1.1 x1.1 x1.1 x
USDFY, 2014FY, 2015FY, 2016

Net Income

10.2 m(51.8 m)(60.1 m)

Depreciation and Amortization

155 k435 k808 k

Accounts Receivable

(395 k)(760 k)490 k

Inventories

(97.8 m)(153.7 m)2.1 m

Accounts Payable

1.5 m(788 k)502 k

Cash From Operating Activities

(24.2 m)(28.3 m)(48.1 m)

Purchases of PP&E

(1.3 m)(1.4 m)(1.6 m)

Cash From Investing Activities

(97.4 m)8.1 m(26.7 m)

Cash From Financing Activities

47 m10.8 m65.4 m

Interest Paid

279 k279 k

Income Taxes Paid

341 k4.7 m
Y, 2016

Financial Leverage

1.1 x

Adamas Pharmaceuticals Market Value History

Adamas Pharmaceuticals Company Life and Culture

You may also be interested in